Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Recruiting

Phase 1

Gamma Delta T-cell Infusion with CyclophosphamideExpanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Sponsor:

University of Kansas Medical Center

Code:

NCT03533816

Conditions

Acute Myeloid Leukemia

Chronic Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplastic Syndromes

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

EAGD T-cell infusion (Phase I)

EAGD T-cell infusion (Expansion)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-18. This information was provided to ClinicalTrials.gov by University of Kansas Medical Center on 2026-03-25.